Syqe Medical, a developer of medical devices, announced this week the signing of an agreement with the Israeli Ministry of Defense to supply the SyqeAir inhalers and cartridges to all veterans prescribed medical cannabis. This first-of-its-kind agreement allows veterans to directly obtain medical cannabis in the same way they access pharmaceutical drugs, and signals the Israeli military officially recognizing the medical benefits of cannabis.
“We are proud of the strategic partnership with the Ministry of Defense and the opportunity to bring our breakthrough technology, the SyqeAir Inhaler, to veterans in need of medical cannabis treatment,” says Hagit Kamin, CEO of Tel Aviv-based SyqeAir. ”It is our privilege to help veterans who mainly suffer from chronic pain and PTSD to establish a functioning daily routine for themselves.”
SyqeAir’s devices comprise a patented, metered-dose system that accurately controls the amount of cannabis delivered for precise dosing and a high level of patient control. The SyqeAir Inhaler is CE (European standard) and MDL (Health Canada) approved and clinically validated by 3 clinical trials and research demonstrating their safety and efficacy. The pre-loaded cartridge contains 60 uniform doses of pharmaceutical-grade, standardized raw cannabis flowers grown by the Dutch company Bedrocan — a supplier of standardised medicinal cannabis.
“It’s been a long journey to get to this point, but it’s truly rewarding to see the impact that the SyqeAir Inhaler has on the lives of our patients,” says Jacob Vogel, Director of Global Sales and Business Development, SyqeAir. “We hope this partnership will serve as a model for other countries to follow in providing veterans with the best possible medical care.”